Naproxcinod

Drug Profile

Naproxcinod

Alternative Names: AZD 3582; HCT 3012; Naproxen nitroxybutylester; Nitronaproxen; NO-naproxen

Latest Information Update: 12 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NicOx
  • Class Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Osteoarthritis
  • Discontinued Duchenne muscular dystrophy

Most Recent Events

  • 10 Nov 2015 Naproxcinod licensed to Fera Pharmaceuticals in USA
  • 28 Aug 2015 Discontinued - Preclinical for Duchenne muscular dystrophy in USA (PO)
  • 19 Mar 2015 Naproxcinod receives Orphan Drug status for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top